LONDON - Biocompatibles International plc sealed a deal with AstraZeneca plc worth a potential €302.3 million (US$422.6 million) for a glucagon-like peptide (GLP-1) analogue for treating diabetes and obesity. (BioWorld International)
No Abstract BioWorld International CorrespondentThe Oslo Cancer Cluster, a Norwegian industry and research cluster focused on oncology, is seeking a €300 million (US$418 million) government bailout to help the country's fledgling biotechnology sector to weather the international financial crisis.
RSS